Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 354

1.

A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.

Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.

Bioconjug Chem. 2005 Jan-Feb;16(1):200-7.

PMID:
15656592
[PubMed - indexed for MEDLINE]
2.

Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.

Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.

Bioconjug Chem. 2008 Jan;19(1):299-305. Epub 2007 Nov 20.

PMID:
18020402
[PubMed - indexed for MEDLINE]
3.

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.

Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.

Bioconjug Chem. 2006 May-Jun;17(3):618-30.

PMID:
16704199
[PubMed - indexed for MEDLINE]
4.

Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.

Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN.

Bioconjug Chem. 2005 Sep-Oct;16(5):1291-8.

PMID:
16173810
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Structural and biologic characterization of pegylated recombinant IFN-alpha2b.

Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, Jacobs S, Brassard D, Bausch J, Bordens R.

J Interferon Cytokine Res. 2001 Dec;21(12):1103-15.

PMID:
11798469
[PubMed - indexed for MEDLINE]
6.

Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.

Jo YW, Youn YS, Lee SH, Kim BM, Kang SH, Yoo M, Choi EC, Lee KC.

Int J Pharm. 2006 Feb 17;309(1-2):87-93. Epub 2006 Jan 9.

PMID:
16406701
[PubMed - indexed for MEDLINE]
7.

Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.

Lee JI, Eisenberg SP, Rosendahl MS, Chlipala EA, Brown JD, Doherty DH, Cox GN.

J Interferon Cytokine Res. 2013 Dec;33(12):769-77. doi: 10.1089/jir.2012.0148. Epub 2013 Aug 20.

PMID:
23962003
[PubMed - indexed for MEDLINE]
8.

Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.

Hu J, Duppatla V, Harth S, Schmitz W, Sebald W.

Bioconjug Chem. 2010 Oct 20;21(10):1762-72. doi: 10.1021/bc9005706.

PMID:
20886828
[PubMed - indexed for MEDLINE]
9.

Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.

Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y.

J Med Chem. 2004 Sep 23;47(20):4897-904.

PMID:
15369394
[PubMed - indexed for MEDLINE]
10.

Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.

Natarajan A, Xiong CY, Albrecht H, DeNardo GL, DeNardo SJ.

Bioconjug Chem. 2005 Jan-Feb;16(1):113-21.

PMID:
15656582
[PubMed - indexed for MEDLINE]
11.

Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS, Martin P.

J Pharmacol Exp Ther. 2001 Jun;297(3):1059-66.

PMID:
11356929
[PubMed - indexed for MEDLINE]
Free Article
12.

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

Grace MJ, Lee S, Bradshaw S, Chapman J, Spond J, Cox S, Delorenzo M, Brassard D, Wylie D, Cannon-Carlson S, Cullen C, Indelicato S, Voloch M, Bordens R.

J Biol Chem. 2005 Feb 25;280(8):6327-36. Epub 2004 Dec 13.

PMID:
15596441
[PubMed - indexed for MEDLINE]
Free Article
13.

Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.

Youngster S, Wang YS, Grace M, Bausch J, Bordens R, Wyss DF.

Curr Pharm Des. 2002;8(24):2139-57. Review.

PMID:
12369859
[PubMed - indexed for MEDLINE]
14.

Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.

Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN.

Exp Hematol. 2006 Jun;34(6):697-704.

PMID:
16728273
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

PEGylation Improves the Pharmacokinetic Properties and Ability of Interferon Gamma to Inhibit Growth of a Human Tumor Xenograft in Athymic Mice.

Fam CM, Eisenberg SP, Carlson SJ, Chlipala EA, Cox GN, Rosendahl MS.

J Interferon Cytokine Res. 2014 May 19. [Epub ahead of print]

PMID:
24841172
[PubMed - as supplied by publisher]
16.

A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.

Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH.

Endocrinology. 2007 Apr;148(4):1590-7. Epub 2007 Jan 18.

PMID:
17234711
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Identification of the major positional isomer of pegylated interferon alpha-2b.

Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF.

Biochemistry. 2000 Sep 5;39(35):10634-40.

PMID:
10978146
[PubMed - indexed for MEDLINE]
18.

Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.

Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S.

Bioconjug Chem. 2007 Jan-Feb;18(1):61-76.

PMID:
17226958
[PubMed - indexed for MEDLINE]
19.

Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.

Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li M, Si D, Luo H, Zeng Y, Fu P, Liu C.

Regul Pept. 2012 Jan 10;173(1-3):74-81. doi: 10.1016/j.regpep.2011.09.008. Epub 2011 Oct 8.

PMID:
21985916
[PubMed - indexed for MEDLINE]
20.

Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.

Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T.

Biochem Biophys Res Commun. 2004 Mar 19;315(4):808-14.

PMID:
14985084
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk